Companies Dominating the Heparinâ€induced Thrombocytopenia Landscape
- Endo International plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PlateletBio
- AUROMEDICS PHARMA LLC
- Fresenius Kabi USA
- Pfizer Inc
- Caplin Steriles Ltd
- Hikma Pharmaceuticals PLC
- Teva Pharmaceuticals Industries Limited
- NOVARTIS AG
- Eagle Pharmaceutical Inc
- WEST WARD INC
Browse Key Market Insights with Data Illustration:
In the News
- Par Sterile Products, a subsidiary of Endo International plc, began to dispatch argatroban to healthcare providers via the Premier ProRx private label program, an insured reserve for hospitals and health systems.
- Platelet Bio, a biotechnology company dedicated to the discovery and development of an innovative platform for allogeneic cell therapy based on platelet biology, successfully raised $75.5 million in Series B funding in November 2021. Contributions from new investors, SymBiosis, K2 HealthVentures, and Oxford Finance were also part of this funding round together with the ongoing support provided by existing investors. The company intends to use the proceeds of this financing, which represents groundbreaking treatment for immune thrombocytopenia, an autoimmunity disease, to advance the preclinical development of its flagship program on platelets-like cells. In addition, Platelet Bio intends to further develop its innovative engineered PLC platform and improves its manufacturing capabilities.
